Qrons (QRON) EBITDA Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Qrons EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qrons's EBITDA for the three months ended in Sep. 2024 was $-0.06 Mil. Qrons's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Qrons's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.

Qrons EBITDA Margin % Historical Data

The historical data trend for Qrons's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qrons EBITDA Margin % Chart

Qrons Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

Qrons Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Qrons's EBITDA Margin %

For the Biotechnology subindustry, Qrons's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qrons's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qrons's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Qrons's EBITDA Margin % falls into.

Qrons EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Qrons's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-0.684	/	0
	=	%

Qrons's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.056	/	0
	=	%

Qrons (OTCPK:QRON) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Qrons EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Qrons's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Qrons Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

28-10 Jackson Avenue, No. 26N, Long Island, NY, USA, 11101

Website

https://www.qrons.com

Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.

Executives

John N Bonfiglio	officer: Chief Operating Officer	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer	director, 10 percent owner, officer: CEO, CFO and Secretary	28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld	director, 10 percent owner, officer: President	153 HAGILBOA STREET, NIRIT L3 44805